Who are TNFa Antagonist - Adalimumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TNFa Antagonist - Infliximab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tnfa-antagonist-adalimumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

TNFa Antagonist - Adalimumab — Competitive Intelligence Brief

TNFa Antagonist - Adalimumab (TNFa Antagonist - Adalimumab) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-α antagonist (monoclonal antibody). Area: Immunology.

marketed TNF-α antagonist (monoclonal antibody) TNF-α (Tumor Necrosis Factor-alpha) Immunology Biologic Live · refreshed every 30 min

Target snapshot

TNFa Antagonist - Adalimumab (TNFa Antagonist - Adalimumab) — University of Calgary. Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TNFa Antagonist - Adalimumab TARGET	TNFa Antagonist - Adalimumab	University of Calgary	marketed	TNF-α antagonist (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)
TNFa Antagonist - Infliximab	TNFa Antagonist - Infliximab	University of Calgary	marketed	TNF-α antagonist (monoclonal antibody)	TNF-α (Tumor Necrosis Factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-α antagonist (monoclonal antibody) class)

University of Calgary · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TNFa Antagonist - Adalimumab — Competitive Intelligence Brief. https://druglandscape.com/ci/tnfa-antagonist-adalimumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab